These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31983295)

  • 1. Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
    Aher RB; Sarkar D
    J Biomol Struct Dyn; 2021 Feb; 39(3):889-900. PubMed ID: 31983295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretomanid for the treatment of pulmonary tuberculosis.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Oct; 56(10):655-668. PubMed ID: 33185630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of antimalarial transmission blocking agents: Pharmacophore mapping of ligands active against stage-V mature gametocytes of
    Aher RB; Roy K
    J Biomol Struct Dyn; 2019 Sep; 37(14):3660-3673. PubMed ID: 30238847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The
    Mansjö M; Karlsson Lindsjö O; Grönfors Seeth C; Groenheit R; Werngren J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0102622. PubMed ID: 36409105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice.
    Nguyen TVA; Nguyen QH; Nguyen TNT; Anthony RM; Vu DH; Alffenaar JC
    Int J Antimicrob Agents; 2023 Oct; 62(4):106953. PubMed ID: 37595848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
    Deb U; Biswas S
    Indian J Tuberc; 2021 Apr; 68(2):287-291. PubMed ID: 33845969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic
    Mota F; Ruiz-Bedoya CA; Tucker EW; Holt DP; De Jesus P; Lodge MA; Erice C; Chen X; Bahr M; Flavahan K; Kim J; Brosnan MK; Ordonez AA; Peloquin CA; Dannals RF; Jain SK
    Nat Commun; 2022 Dec; 13(1):7974. PubMed ID: 36581633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
    Adeniji AA; Knoll KE; Loots DT
    Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
    Villar R; Vicente E; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
    J Antimicrob Chemother; 2008 Sep; 62(3):547-54. PubMed ID: 18502817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delamanid or pretomanid? A Solomonic judgement!
    Mudde SE; Upton AM; Lenaerts A; Bax HI; De Steenwinkel JEM
    J Antimicrob Chemother; 2022 Mar; 77(4):880-902. PubMed ID: 35089314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
    Rakesh ; Bruhn DF; Scherman MS; Singh AP; Yang L; Liu J; Lenaerts AJ; Lee RE
    Bioorg Med Chem Lett; 2016 Jan; 26(2):388-391. PubMed ID: 26711150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines.
    Saxena AK; Alam M
    Curr Top Med Chem; 2020; 20(29):2723-2734. PubMed ID: 32885753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
    Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
    Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
    López-Gavín A; Tudó G; Vergara A; Hurtado JC; Gonzalez-Martín J
    Int J Antimicrob Agents; 2015 Nov; 46(5):582-5. PubMed ID: 26421981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
    Gold B; Roberts J; Ling Y; Quezada LL; Glasheen J; Ballinger E; Somersan-Karakaya S; Warrier T; Warren JD; Nathan C
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6521-38. PubMed ID: 26239979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.